Imaging Agents to Monitor the Distribution of Therapies Delivered to the Brain
Background:
The National Institute of
Neurological Disorders and Stroke (NINDS) seeks a commercial
collaborator to work with NINDS in the development and
commercialization of surrogate markers for monitoring the spatial
distribution of therapeutic substances by (more...)
(Full Text)
Anakin Protein as a Prognostic Tool for Diagnosing Breast Cancer Outcome
Available for collaborative research toward commercial
development and/or exclusive and non-exclusive
licensing:
Method of diagnosis for early metastasis and
therapeutic inhibition of metastasis.
Nucleic acid sequence of Anakin protein, an
extracellular matrix (ECM) modifier gene.
SiRNA sequences (more...)
(Full Text)
Bioinformatic Tools for Genomic DNA Sequence Dimorphisms (Indels)
Background:
The National Cancer Institute,
Center for Cancer Research, Mouse Cancer Genetics Program is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize identification and use (more...)
(Full Text)
Identification of T-Cell Receptors (TCR)
Background:
The NIH National Cancer
Institute's Surgery Branch seeks a research partner to further
develop, evaluate, or commercialize adoptive immunotherapy
therapeutics under a Collaboration Agreement or a Cooperative
Research and Development Agreement (CRADA).
Technology:
Adoptive immunotherapy
circumvents a (more...)
(Full Text)
Diagnosis and Therapeutic Monitoring of Cancer Using Beta-Catenin Splice Variants
Background:
The National Cancer Institute,
Division of Cancer Epidemiology and Genetics is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize a method of
diagnosing or (more...)
(Full Text)
Method for Predicting and Detecting Tumor Metastasis
Background:
The National Institute of Child Health and Human Development's
Laboratory of Development Neurobiology is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize methods (more...)
(Full Text)
Inhibitors for Metastasized Breast Cancers
Background:
The National Cancer Institute's Laboratory of
Molecular Pharmacology is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize histone deacetylase
(HDAC) inhibitor (HDI) for breast (more...)
(Full Text)
Methods of Glycosylation and Bioconjugation
Background:
The National Cancer Institute's
Structural Glycobiology Laboratory is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, and/or commercialize methods
of glycosylation and bioconjugation that can be (more...)
(Full Text)
Selenocysteine Enables a New Platform for Immunoconjugates
The Experimental
Transplantation and Immunology Branch of the National Cancer
Institute is seeking statements of capability or interest from
parties interested in forming a collaborative research alliance to
further develop, evaluate, or commercialize a new
platform technology (more...)
(Full Text)
Nanoantibodies as Therapeutics and Diagnostics
Background:
The National Cancer Institute
Center for Cancer Research Nanobiology Program is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize nanoantibodies as therapeutics or diagnostics.
The (more...)
(Full Text)
Human Monoclonal Antibody Against Mesothelin
Background:
The National Cancer Institute's
Nanobiology Program is seeking statements of capability or interest
from parties interested in collaborative research to further
develop, evaluate, or commercialize human antibodies that act
against mesothelin.
NIH inventors have demonstrated (more...)
(Full Text)
Methods and Compositions for the Diagnosis of Neuroendocrine Lung Cancer
Background:
The National Cancer Institute's
Laboratory of Human Carcinogenesis is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize methods for
the diagnosis of neuroendocrine lung (more...)
(Full Text)
Molecular Diagnostics for Breast Cancer Precursors
Background:
The National Cancer Institute,
Genetics Branch is seeking statements of capability or interest
from parties interested in collaborative research to further
develop, evaluate, or commercialize a method of profiling ductal
carcinoma of the breast.
The (more...)
(Full Text)
Optical Cells with Biological Applications
Background:
NICHD is seeking statements of
capability or interest from parties interested in collaborative
research and/or partnership agreements to develop, evaluate, or
commercialize optical cells with tissue pathology diagnostic
applications. Apart from pathology diagnostics, potential
applications (more...)
(Full Text)
Cell Lines For Angiogenesis Screening
Background:
The National Cancer Institute's Angiogenesis Core Facility is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize multicolored fluorescent cell lines and software
for high-throughput (more...)
(Full Text)
Cripto-1 as a Biomarker for Cardiac Ischemia
Description of Technology:
This technology describes Cripto-1 as a biomarker for infarcted
cardiac tissues. Cripto-1 is a member of the epidermal growth
factor (EGF)-related proteins and is currently thought to play an
important role (more...)
(Full Text)
Sugar Substrates For Targeted-Drug Delivery
Background:
The National Cancer Institute's Nanobiology Program is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize the synthesis of UDP derivatives of C2 modified
galactose (more...)
(Full Text)
Biomarkers For Birt-Hogg-Dube (BHD) Syndrome And Renal Cancer
Background:
The National Cancer Institute's Urologic Oncology Branch is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize detection methods to screen a biomarker for (more...)
(Full Text)
Antibody-Based Cancer Biomarkers And Therapeutic Agents
Background:
The National Cancer Institute's Mammary Biology and Tumorigenesis
Laboratory is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize isoform-specifc antibodies to the human
prolactin (more...)
(Full Text)
Personalized Medicine Approach To Assessing Cancer Prevention Properties Of Statins
Background:
The National Cancer Institute's Chemopreventive Agent Development
Research Group is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize methods to assess reduction of (more...)
(Full Text)
Metabolic Biomarkers To Detect Exposure To Gamma Radiation
Background:
The National Cancer Institute's Laboratory of Metabolism is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize the development of biomarkers for radiation exposure
and (more...)
(Full Text)
cDNA Fragments As Novel Anti-Cancer Therapeutics And Diagnostics
Background:
The National Cancer Institute's Hatfield Clinical Research Center
is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize cDNA fragments as antiangiogenic and antitumor
therapy.
Technology:
This (more...)
(Full Text)
Method For Detection Of Cancer Based On Spatial Genome Organization In The Cell Nucleus
Background:
The National Cancer Institute's Cell Biology of Genomes Group is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize diagnostic methods for detection of (more...)
(Full Text)
Methods For Accurately Measuring And Regulating Adrenomedullin
Background:
The National Cancer Institute's Angiogenesis Core Facility is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize methods to detect or regulate adrenomedullin (AM)
levels. (more...)
(Full Text)
A Simple Genetic Test For Kidney Disease
Background:
The National Cancer Institute's Laboratory of Genomic Diversity is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize genetic testing for kidney disease.
Technology:
An estimated (more...)
(Full Text)
Method For Effiecient Delivery Of Proteins Into Cells
Therapeutics To Treat Ocular Diseases
Monoclonal Antibodies Against B-Cell Chronic Lymphocytic Leukemia (B-CLL) Tumors
TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.